RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT

Clinical trials for RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT explained in plain language.

Never miss a new study

Get alerted when new RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT trials appear

Sign up with your email to follow new studies for RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Drug-Radiation combo tested for aggressive brain cancers that return

Disease control Recruiting now

This early-stage trial is testing whether combining an experimental drug called triapine with radiation therapy is safe for adults with glioblastoma or astrocytoma brain tumors that have returned after previous treatment. The study aims to find the highest dose of triapine that c…

Matched conditions: RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 25, 2026 14:08 UTC

RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT

Get alerted when new RECURRENT ADULT DIFFUSE MIDLINE GLIOMA, H3 K27-MUTANT trials appear

New Drug-Radiation combo tested for aggressive brain cancers that return